Status:
COMPLETED
EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
First People's Hospital of Hangzhou
Conditions:
Pancreatic Adenocarcinoma Non-resectable
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.
Detailed Description
The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency ...
Eligibility Criteria
Inclusion
- Patients in the age group 20 to 80 years
- A cytological or histological diagnosis of inoperable PDAC based on multidisciplinary review of cross sectional imaging and cytology or histology results.
- Patients who have been deemed unfit for surgical resection of the PDAC subjects who are fit for surgical resection but have declined surgery will also be considered for the study
- PDAC patients presenting with jaundice to be considered after a successful biliary drainage
- Patients ought to be fit enough to be considered for the study (ECOG performance status 0, 1 or 2)
- Patients capable of giving informed consent
Exclusion
- Inability to give informed consent
- Pregnancy or breast feeding
- ECOG performance status 3 or 4
- Life expectancy less than 3 months
- Patients with distant metastases or malignant ascites
Key Trial Info
Start Date :
December 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2021
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03772756
Start Date
December 20 2018
End Date
August 16 2021
Last Update
August 30 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Jianfeng Yang
Hangzhou, Zhejiang, China, 310006
2
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China, 31006